Skip to main content

Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.

Journal articles  - Journal Article
Karlin, KL; Gilbert, EH; Lim, F; Agyekum, AA; Yang, JY; Faye, AS; Patel, A; Hur, C; Leiman, DA
Published in: Am J Gastroenterol
February 10, 2026

INTRODUCTION: Potassium competitive acid blockers (PCABs) are superior to proton pump inhibitors (PPIs) for healing of Los Angeles (LA) class C/D erosive esophagitis and are approved for nonerosive gastroesophageal reflux disease (GERD) given their efficacy measured by heartburn-free days. However, they are more expensive than PPIs. We estimated the cost-effectiveness of PCABs compared with PPIs for the management of GERD. METHODS: A decision tree was constructed for the base case of a patient with GERD. We tested scenarios in which nonerosive reflux disease, LA A/B, or LA C/D esophagitis was present, comparing PCABs with PPIs as first-line therapy, including step up therapy and/or class switching if symptoms persisted. Using publicly available cost estimates, quality-adjusted life years (QALYs) were compared using a willingness-to-pay threshold of $100,000/QALY from a societal perspective at 6 months. RESULTS: The cost of PCABs for GERD was $3,240 more than PPIs, with an incremental cost-effectiveness ratio of $144,208/QALY. When evaluating GERD phenotypes separately, the incremental cost-effectiveness ratio was consistently over our willingness-to-pay threshold. One-way analyses showed the most influential parameters were PCAB cost and efficacy for heartburn-free days. Probabilistic sensitivity analysis favored PPIs 71.7% out of 100,000 iterations. Reducing one-week costs to below $91 would make PCABs a cost effective first-line strategy across all GERD phenotypes. DISCUSSION: Despite PCAB efficacy, PPIs are a cost-effective strategy for GERD treatment, and can be positioned ahead of PCAB escalation on this basis. Reducing PCAB costs or accepting a higher willingness-to-pay threshold would influence this finding, although PCABs may be favored in some current situations as evidenced by probabilistic sensitivity results.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Gastroenterol

DOI

EISSN

1572-0241

Publication Date

February 10, 2026

Location

United States

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Karlin, K. L., Gilbert, E. H., Lim, F., Agyekum, A. A., Yang, J. Y., Faye, A. S., … Leiman, D. A. (2026). Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease. Am J Gastroenterol. https://doi.org/10.14309/ajg.0000000000003943
Karlin, Kate L., Ella H. Gilbert, Francesca Lim, Alice A. Agyekum, Jeong Yun Yang, Adam S. Faye, Amit Patel, Chin Hur, and David A. Leiman. “Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.Am J Gastroenterol, February 10, 2026. https://doi.org/10.14309/ajg.0000000000003943.
Karlin KL, Gilbert EH, Lim F, Agyekum AA, Yang JY, Faye AS, et al. Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease. Am J Gastroenterol. 2026 Feb 10;
Karlin, Kate L., et al. “Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.Am J Gastroenterol, Feb. 2026. Pubmed, doi:10.14309/ajg.0000000000003943.
Karlin KL, Gilbert EH, Lim F, Agyekum AA, Yang JY, Faye AS, Patel A, Hur C, Leiman DA. Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease. Am J Gastroenterol. 2026 Feb 10;

Published In

Am J Gastroenterol

DOI

EISSN

1572-0241

Publication Date

February 10, 2026

Location

United States

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences